Modulation of drug resistance in ovarian cancer cells by inhibition of protein kinase C-alpha (PKC-α) with small interference RNA (siRNA) agents

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 8, 2012, Pages 3631-3636

  Zhao, Li Jun ^a   Xu, Heng ^b,c   Qu, Jun Wei ^a   Zhao, Wan Zhou ^d   Zhao, Yi Bing ^a   Wang, Jin Hua ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c NANJING TECH UNIVERSITY   (China)

^d Sino EU Biomedical Innovation Center (SEBIC)   (China)

Author keywords

Drug resistance; Mdr1; Ovarian cancer; Pkc ; sirna

Indexed keywords

EID: 84873661183     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.8.3631     Document Type: Article

References (33)

1. Chakrabarty S, Huang S (1996). Modulation of chemosensitivity in human colon carcinoma cells by downregulating protein kinase C α expression. J Exp Ther Oncol, 1, 218-21.
2. Gescher A (1992). Towards selective pharmacological modulation of protein kinase C-opportunities for the development of novel antineoplastic agents. Br J Cancer, 66, 10-9.
3. Ghoul A, Serova M, Benhadji KA, et al. (2005). Protein kinase C α and δ are members of a large kinase family of high potential for novel anticancer targeted therapy, Targeted, Oncol, 1, 42-53.
4. Gill PK, Gescher A, Gant TW (2001). Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes α and Θ. Eur J Biochem, 268, 4151-7.
5. Goldstein LJ (1996). MDR1 gene expression in solid tumours. Eur J Cancer, 32A, 1039-50.
6. Gravitt KR, Ward NE, Fan D, et al. (1994). Evidence that protein kinase C-alpha activation is a critical event in phorbol esterinduced multiple drug resistance in human colon cancer cells. Biochem Pharmacol, 48, 375-81.
7. Guppy AE, Nathan PD, Rustin GJ (2005). Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol), 17, 399-411.
8. Higgins CF (2007). Multiple molecular mechanisms for multidrug resistance transporters. Nature, 446, 749-57.
9. Hofmann J (2001). Modulation of protein kinase C in antitumor treatment. Rev Physiol Biochem Pharmacol, 142, 1-96.
10. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
11. Lage H (2006). MDR1/P glycoprotein (ABCB1) as target for RNA interference mediated reversal of multidrug resistance. Curr Drug Targets, 7, 813-21.
12. Lahn M, Paterson BM, Sundell K, Ma D (2004). The role of protein kinase C-alpha (PKC-α) in malignancies of the gastrointestinal tract. Eur J Cancer, 40, 10-20.
13. Lahn M, Sundell K, Köhler G (2006). The role of protein kinaseC-alpha in hematologic malignancies. Acta Haematol, 115, 1-8.
14. Li L, Xu J, Min T, Huang W (2006). Reversal of MDR1 gene dependent multidrug resistance using low concentration of endonuclease prepared small interference RNA. Eur J Pharmacol, 536, 93-7.
15. Li W, Liu C, Tang Y, et al. (2011). Overexpression of Snail accelerates adriamycin induction of multidrug resistance in breast cancer cells. Asian Pac J Cancer Prev, 12, 2575-80.
16. Liu JP (1996). Protein kinase C and its substrates. Mol Cell Endocrinol, 116, 1-29.
17. Mackay HJ, Twelves CJ (2003). Protein kinase C: a target for anticancer drugs? Endocr Relat Cancer, 10, 389-96.
18. Mahadevan D, Shirahatti N (2005). Strategies for targeting the multidrug resistance 1 (MDR1)/ P gp transporter in human malignancies. Curr Cancer Drug Targets, 5, 445-55.
19. Masanek U, Stammler G, Volm M (2002). Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoportein 170 and PKC isoenzymes with antisense oligonucleotides. J Exp Ther Oncol, 2, 37-41.
20. Mayur YC, Peters GC, Prasad W, Lemo C, Sathish NK (2009). Design of new drug molecules to be used in reversing multidrug resistance in cancer cells. Curr Cancer Drug Targets, 9, 298-306.
21. Nieth C, Priebsch A, Stege A, Lage H (2003). Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett, 545, 144-50.
22. Nishizuka Y (1988). The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature, 334, 661-5.
23. O'Brian C, Vogel VG, Singletary SE, Ward NE (1989). Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res, 49, 3215-17.
24. Ozols RF (2002). Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol, 20, 1161-3.
25. Parekh DB, Ziegler W, Parker PJ (2000). Multiple pathways control protein kinase C phosphorylation. EMBO J, 19, 496-503.
26. Persidis A (1999). Cancer multidrug resistance. Nat Biotechnol, 17, 94-5.
27. Rao DN, Anuradha C, Vishnupriya S, et al. (2010). Association of an MDR1 gene (C3435T) polymorphism with acute leukemia in India. Asian Pac J Cancer Prev, 11, 1063-6.
28. Reynolds A, Leake D, Boese Q, et al. (2004). Rational siRNA design for RNA interference, Nat Biotechnol, 22, 326-30.
29. Shih SC, Mullen A, Abrams K, Mukhopadhyay D, Claffey KP (1999). Role of protein kinase C isoforms in phorbol esterinduced vascular endothelial growth factor expression in human glioblastoma cells. J Biol Chem, 274, 15407-14.
30. Wang J, Zhao W, Chen X, et al. (2010). Establishment of Taxol resistance ovarian carcinoma cell line OV1228/Taxol. Chin J Cancer Prev Treat, 17, 1920-23.
31. Wang J, Zhao W, Chen X, et al. (2010). Establishment and biological characterization of Cisplatin-resistant cell line OV1228/cDDP of ovarian carcinoma. Chin Cancer Res Clinic, 22, 281-4.
32. Yu G, Ahmad S, Aquino A, Fairchild CR, et al. (1991). Transfection with protein PKC α confers increased multidrug resistance to MCF-7 cells expressing P -glycoprotein. Cancer Commun, 3, 181-9.
33. Zaugg K, Rocha S, Resch H, et al. (2001). Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. Cancer Res, 61,732-8.